Macular degeneration trials in China

In China 37 Also abroad 218

37 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Effect of Video Viewing on Intravitreal Injection Experience
Where
Hangzhou
Age
18 years and over
People
182
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07002372
No phaseNot yet taking people in China
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
Where
Guangzhou
People
9,999
Run by
Zhongshan Ophthalmic Center, Sun Yat-sen University
See details and how to joinNCT06918028
Early phase 1Not yet taking people in China
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
Where
Xingtai, Yiwu
Age
50 years and over
People
8
Run by
Guangzhou Jiayin Biotech Ltd
See details and how to joinNCT06888492
Early phase 1Taking people
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Where
Shanghai, Tianjin
Age
50 years to 80 years
People
12
Run by
HuidaGene Therapeutics Co., Ltd.
See details and how to joinNCT06031727
Phase 2Not yet taking people in China
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
Where
Beijing
Age
50 years to 85 years
People
40
Run by
Beijing Anlong Biopharmaceutical Co., Ltd.
See details and how to joinNCT06839339
No phaseTaking people
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
Where
Beijing
Age
50 years and over
People
21
Run by
Beijing Anlong Biopharmaceutical Co., Ltd.
See details and how to joinNCT06718816
Phase 1/2Taking people
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Where
Tianjin
Age
50 years to 85 years
People
44
Run by
Chengdu Origen Biotechnology Co., Ltd.
See details and how to joinNCT06458595
Phase 1/2Taking people
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Where
Beijing
Age
50 years to 85 years
People
42
Run by
Chengdu Origen Biotechnology Co., Ltd.
See details and how to joinNCT05672121
Phase 1/2Taking people
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Where
Tianjin
Age
50 years and over
People
48
Run by
Shanghai Refreshgene Technology Co., Ltd.
See details and how to joinNCT06141460
Phase 1/2Taking people
Gene Therapy(FT-003) for Wet AMD
Where
Tianjin
Age
50 years to 80 years
People
78
Run by
Frontera Therapeutics
See details and how to joinNCT06492863
Phase 1Taking people
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
Where
Beijing
Age
50 years to 75 years
People
10
Run by
Beijing Tongren Hospital
See details and how to joinNCT05445063
No phaseNot yet taking people in China
Observation of the Natural Course of Age-related Macular Degeneration
Where
Shanghai
Age
50 years to 85 years
People
500
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT05418231